Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-31

Clinical Trial Update: Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 randomized trial of cellular immunotherapy for COVID-19–related acute respiratory distress syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cellular Immuno-Therapy

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Covid19, Acute Respiratory Distress Syndrome | Phase 2 | Status: COMPLETED